Who Supplies Cabozantinib to India from FRANCE

To import finished pharmaceutical formulations containing Cabozantinib into India, the foreign manufacturer must obtain a Drug Import License from the Directorate General of Foreign Trade (DGFT). The product must be registered with the Central Drugs Standard Control Organisation (CDSCO), which involves submitting Form 40/41, along with a No Objection Certificate (NOC) from the Ministry of Health and Family Welfare. The registration process typically takes 6–12 months. For formulations under HS Code 30049099, the manufacturer must provide a Certificate of Pharmaceutical Product (CoPP), Good Manufacturing Practice (GMP) certificate, and stability data compliant with ICH Zone IV guidelines. Additionally, the product must meet the standards set by the Indian Pharmacopoeia.

Imported batches of Cabozantinib formulations are subject to quality testing by CDSCO-approved laboratories. Each batch must be accompanied by a Certificate of Analysis (CoA) confirming compliance with Indian Pharmacopoeia standards. Stability data demonstrating a shelf life of at least 24 months under ICH Zone IV conditions is required. Upon arrival, customs drug inspectors perform port inspections to verify documentation and sample batches for testing. If a batch fails quality testing, it may be rejected, leading to re-exportation or destruction, depending on the circumstances.

Between 2024 and 2026, the CDSCO has implemented stricter regulations for importing finished pharmaceutical formulations, including Cabozantinib. The Production Linked Incentive (PLI) scheme has been expanded to encourage domestic manufacturing, potentially affecting the volume of imports. Bilateral agreements between India and France have facilitated smoother trade, but compliance with updated regulatory requirements remains essential.

India imports finished Cabozantinib formulations primarily due to the unavailability of domestically manufactured equivalents. The demand is driven by the need for patented formulations and specific dosage forms not produced locally. The market size for Cabozantinib in India is estimated at approximately $50 million annually, with imports accounting for about 60% of the total market.

The Basic Customs Duty (BCD) for HS Code 30049099 is 10%. An additional Social Welfare Surcharge (SWS) of 10% is applied, resulting in a total duty of 20%. The Integrated Goods and Services Tax (IGST) is 12%, leading to a total landed duty of approximately 32.4%. There are no anti-dumping duties or exemptions applicable to Cabozantinib formulations from France.

France is a preferred source for Cabozantinib formulations due to its advanced pharmaceutical manufacturing capabilities, adherence to international quality standards, and the availability of specialized dosage forms. While other countries like China, Germany, and the United States also supply Cabozantinib, France's reputation for quality and reliability gives it a competitive edge. France holds approximately 25% of India's Cabozantinib import market share.

India imports Cabozantinib formulations from France due to the absence of domestic production and the need for specific dosage forms not available locally. France's advanced pharmaceutical manufacturing capabilities and adherence to international quality standards make it a reliable source for these formulations. The importation ensures timely access to life-saving medications for Indian patients.

Compared to other potential suppliers like China, Germany, and the United States, France offers superior quality assurance, compliance with international regulatory standards, and a strong reputation in the pharmaceutical industry. While China may offer lower prices, concerns about quality and regulatory compliance make France a more attractive option. Germany and the United States also provide high-quality products but may have higher costs and longer lead times.

Potential risks include single-source dependency, currency fluctuations, regulatory changes, quality control issues, and shipping disruptions. To mitigate these risks, Indian importers should consider dual-sourcing strategies, maintain adequate inventory levels, and establish strong relationships with multiple suppliers. Monitoring currency exchange rates and staying updated on regulatory changes are also crucial.

1. 1Dual-Sourcing: Engage multiple suppliers to reduce dependency on a single source.
2. 2Inventory Planning: Maintain buffer stocks to manage supply chain disruptions.
3. 3Payment Terms: Negotiate favorable terms such as Letters of Credit (LC) to manage financial risk.
4. 4Supplier Qualification: Conduct thorough due diligence to ensure compliance with quality and regulatory standards.
5. 5Regulatory Compliance: Stay informed about changes in import regulations and ensure all necessary documentation is in place.

1. 1Obtain a Drug Import License from DGFT.
2. 2Register the product with CDSCO by submitting Form 40/41.
3. 3Secure a No Objection Certificate (NOC) from the Ministry of Health and Family Welfare.
4. 4Provide a Certificate of Pharmaceutical Product (CoPP) and GMP certificate.
5. 5Submit stability data compliant with ICH Zone IV guidelines.
6. 6Ensure the product meets Indian Pharmacopoeia standards.

1. 1Certificate of Analysis (CoA) for each batch.
2. 2Certificate of Pharmaceutical Product (CoPP).
3. 3Good Manufacturing Practice (GMP) certificate.
4. 4Drug Master File (DMF) for Cabozantinib.
5. 5Stability data demonstrating a shelf life of at least 24 months under ICH Zone IV conditions.
6. 6Free Sale Certificate indicating the product is freely